Data registry
BehavioralCollection of clinical data, treatment regimens and survival data
NCT Number: NCT04391946
The COVID-19 epidemic (Coronavirus Disease 2019) which is currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). The first cases were reported in Wuhan, China, in late December 2019 [1]. Globally, it has been placed in the "pandemic" stage by the WHO since March 11, 2020. Coronavirus viruses have been responsible for epidemics in the past such as the SARS epidemic in 2002 (Syndrome Severe Acute Respiratory) linked to the SARS-CoV virus, or the epidemic of MERS (Middle East Respiratory Syndrome) that affected the Middle East in 2012.
Patients with chronic lymphocytic leukemia (CLL) / lymphocytic lymphoma or Waldenstrom Disease (WD) therefore represent a population at high risk of developing a severe form in the event of COVID-19 infection.
To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in this population of patients with CLL / lymphocytic lymphoma or WD.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Chu Angers, Angers, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Collection of clinical data, treatment regimens and survival data
Time frame: Day 0
Hematological pathology Description
Time frame: within 12 months after diagnosis
Describe the management carried out concerning Coronavirus infection and its impact on the treatment of hemopathy.
Time frame: through study completion, an average of 2 years
Allow national epidemiological monitoring and regularly inform the hematology community.
French Innovative Leukemia Organisation
Other
National Prospective and Retrospective Follow-up of Patients With COVID-19 Infected Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenström Disease
Acronym: COVID19_LLC-MW
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02337829
Chromosome 17 deletion, Chronic Disease
Bethesda, Maryland, United States
View Trial DetailsNCT01750567
Chronic Disease, Disease Attributes
Ann Arbor, Michigan, United States
View Trial DetailsNCT03480360
Acute Myeloid Leukemia, Anemia
Lebanon, New Hampshire, United States
View Trial DetailsNCT05024045
B-cell Lymphoma, Blood Protein Disorders
Tucson, Arizona, United States
View Trial Details